Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 22

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 22
---
 may any applicable New Issuance Price under this Agreement result in a price per Security that would violate
the rules or regulations of the Principal Market, and the Company shall not undertake any transaction that would result in such a violative
New Issuance Price. The Company shall not issue or sell any Depositary Shares pursuant to this Agreement if such issuance or sale would
reasonably be expected to result in a violation of the Securities Act.

(f) . Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell,
and the Investor shall not purchase or acquire, any Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
under this Agreement which, when aggregated with all other Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3
promulgated thereunder), would result in the beneficial ownership by the Investor and its affiliates of more than 4.99%
of the then issued and outstanding Ordinary Shares following such purchase or acquisition by the Investor (including Ordinary Shares represented
by Depositary Shares) (the “”), , the Investor may increase the
Beneficial Ownership Limitation up to 9.99% at its sole discretion upon sixty-one (61) days’ prior written notice to the Company,
and , if as of the Investor and its affiliates holds 5.0% or more of the outstanding Ordinary Shares (including
Ordinary Shares represented by Depositary Shares) as of the Execution Date then Beneficial Ownership Limitation shall be 9.99%. Upon the
written or oral request of the Investor, the Company shall promptly (but not later than the next Business Day on which the Depositary
is open for business) confirm orally or in writing to the Investor the number of Ordinary Shares (including Ordinary Shares represented
by Depositary Shares) then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required
hereby and the application hereof. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership
Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and
such result absent manifest error.

(g) . Notwithstanding any other terms of this Agreement, in no event shall the aggregate amount of Purchase Shares
submitted in any single or combination of VWAP Purchase Notices and/or Additional VWAP Purchase